| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.813 | 0.003 | 0.813 | 5 Hydroxytryptamine release stimulant | 0.243 0.093 DBMET00900 0.215 0.11 DBMET00927 | ||
| 0.801 | 0.005 | 0.801 | Antiobesity | 0.486 0.04 DBMET00900 0.786 0.006 DBMET00927 | ||
| 0.797 | 0.002 | 0.797 | 5 Hydroxytryptamine 2C agonist | 0.222 0.004 DBMET00900 0.087 0.009 DBMET00927 | ||
| 0.787 | 0.001 | 0.787 | 5 Hydroxytryptamine 2B agonist | 0.075 0.005 DBMET00900 | ||
| 0.767 | 0.004 | 0.767 | 5 Hydroxytryptamine agonist | 0.1 0.033 DBMET00900 | ||
| 0.723 | 0.002 | 0.723 | 5 Hydroxytryptamine 2 agonist | 0.061 0.025 DBMET00900 | ||
| 0.66 | 0.002 | 0.66 | 5 Hydroxytryptamine 2A agonist | 0.062 0.045 DBMET00900 | ||
| 0.524 | 0.043 | 0.524 | Analgesic | |||
| 0.47 | 0.005 | 0.47 | 5 Hydroxytryptamine uptake stimulant | 0.216 0.123 DBMET00900 | ||
| 0.45 | 0.042 | 0.45 | GABA C receptor rho-3 antagonist | |||
| 0.42 | 0.019 | 0.42 | Psychostimulant | |||
| 0.414 | 0.02 | 0.414 | Calcium channel activator | 0.254 0.142 DBMET00900 | ||
| 0.386 | 0.005 | 0.386 | 5 Hydroxytryptamine uptake inhibitor | |||
| 0.383 | 0.024 | 0.383 | Sigma receptor agonist | |||
| 0.339 | 0.004 | 0.339 | GABA C receptor antagonist | 0.146 0.032 DBMET00900 | ||
| 0.406 | 0.077 | 0.406 | Calcium channel L-type activator | |||
| 0.325 | 0.005 | 0.325 | NMDA receptor antagonist | |||
| 0.324 | 0.008 | 0.324 | 5 Hydroxytryptamine 2C antagonist | |||
| 0.329 | 0.014 | 0.329 | 5 Hydroxytryptamine 2 antagonist | |||
| 0.328 | 0.022 | 0.328 | Tyrosine 3 hydroxylase inhibitor | |||
| 0.317 | 0.017 | 0.317 | 5 Hydroxytryptamine antagonist | |||
| 0.318 | 0.02 | 0.318 | 5 Hydroxytryptamine 1E antagonist | 0.219 0.109 DBMET00900 | ||
| 0.308 | 0.013 | 0.308 | Acetylcholine M1 receptor antagonist | 0.12 0.109 DBMET00900 | ||
| 0.286 | 0.004 | 0.286 | MAP-kinase-activated kinase inhibitor | |||
| 0.279 | 0.004 | 0.279 | Adrenaline uptake inhibitor | |||
| 0.369 | 0.1 | 0.369 | 5 Hydroxytryptamine release inhibitor | 0.249 0.229 DBMET00927 | ||
| 0.343 | 0.077 | 0.343 | Vasodilator, peripheral | |||
| 0.309 | 0.047 | 0.309 | HERG channel blocker | |||
| 0.263 | 0.004 | 0.263 | MAP-kinase-activated kinase 2 inhibitor | |||
| 0.297 | 0.041 | 0.297 | Anticonvulsant | |||
| 0.292 | 0.052 | 0.292 | Potassium channel (Voltage-sensitive) blocker | |||
| 0.234 | 0.003 | 0.234 | Nicotinic alpha3beta2 receptor antagonist | |||
| 0.272 | 0.041 | 0.272 | Anesthetic general | |||
| 0.231 | 0.007 | 0.231 | HIV-1 integrase (Overall Integration) inhibitor | 0.121 0.039 DBMET00900 | ||
| 0.234 | 0.017 | 0.234 | Alpha 2b adrenoreceptor antagonist | |||
| 0.232 | 0.021 | 0.232 | 5 Hydroxytryptamine 2B antagonist | |||
| 0.25 | 0.039 | 0.25 | Neurotrophic factor enhancer | 0.149 0.139 DBMET00927 | ||
| 0.221 | 0.012 | 0.221 | Alpha 2a adrenoreceptor antagonist | |||
| 0.201 | 0.004 | 0.201 | Nicotinic alpha4beta2 receptor antagonist | |||
| 0.223 | 0.027 | 0.223 | Cholinergic antagonist | |||
| 0.219 | 0.024 | 0.256 | ATPase inhibitor | 0.256 0.012 DBMET00927 | DBMET00927 | |
| 0.22 | 0.026 | 0.22 | Acetylcholine antagonist | |||
| 0.211 | 0.018 | 0.211 | 5 Hydroxytryptamine 2A antagonist | |||
| 0.191 | 0.007 | 0.191 | Dopamine uptake inhibitor | |||
| 0.22 | 0.037 | 0.22 | Antipruritic | |||
| 0.207 | 0.025 | 0.207 | GABA C receptor rho-2 antagonist | |||
| 0.201 | 0.02 | 0.201 | GABA C receptor agonist | |||
| 0.255 | 0.075 | 0.255 | Interleukin agonist | |||
| 0.185 | 0.005 | 0.185 | NMDA 2C receptor antagonist | |||
| 0.237 | 0.058 | 0.237 | RNA-directed DNA polymerase inhibitor | |||
| 0.184 | 0.007 | 0.184 | Acetylcholine M4 receptor antagonist | |||
| 0.184 | 0.011 | 0.184 | NMDA 2 receptor antagonist | |||
| 0.199 | 0.026 | 0.199 | Glutamate receptor antagonist | |||
| 0.191 | 0.02 | 0.191 | GABA receptor agonist | |||
| 0.188 | 0.019 | 0.188 | Alpha 2 adrenoreceptor antagonist | |||
| 0.193 | 0.026 | 0.193 | Acetylcholine muscarinic antagonist | |||
| 0.175 | 0.012 | 0.175 | Dopamine D1 antagonist | |||
| 0.184 | 0.02 | 0.184 | 5 Hydroxytryptamine 3A agonist | |||
| 0.158 | 0.006 | 0.158 | Glycine receptor antagonist | 0.106 0.027 DBMET00900 0.088 0.046 DBMET00927 | ||
| 0.168 | 0.015 | 0.168 | GABA C receptor rho-1 antagonist | |||
| 0.181 | 0.031 | 0.181 | Alpha adrenoreceptor antagonist | |||
| 0.156 | 0.009 | 0.156 | Lanosterol 14 alpha demethylase inhibitor | |||
| 0.262 | 0.117 | 0.287 | Antithrombotic | 0.287 0.097 DBMET00927 | DBMET00927 | |
| 0.161 | 0.016 | 0.161 | Dopamine D4 antagonist | |||
| 0.185 | 0.048 | 0.185 | Protein kinase stimulant | 0.177 0.051 DBMET00927 | ||
| 0.167 | 0.029 | 0.167 | Pregnane X receptor agonist | |||
| 0.145 | 0.008 | 0.145 | 5 Hydroxytryptamine 5A antagonist | |||
| 0.144 | 0.008 | 0.144 | 5 Hydroxytryptamine 5 antagonist | |||
| 0.135 | 0.005 | 0.135 | NMDA receptor subunit 3A antagonist | |||
| 0.139 | 0.009 | 0.139 | Acetylcholine M5 receptor antagonist | |||
| 0.223 | 0.093 | 0.223 | Aldehyde oxidase inhibitor | |||
| 0.311 | 0.182 | 0.311 | Caspase 9 stimulant | |||
| 0.145 | 0.017 | 0.145 | Inducible nitric-oxide synthase inhibitor | |||
| 0.135 | 0.008 | 0.135 | Alpha 2 adrenoreceptor agonist | |||
| 0.133 | 0.009 | 0.133 | Glycine receptor agonist | 0.084 0.033 DBMET00900 0.077 0.042 DBMET00927 | ||
| 0.166 | 0.044 | 0.166 | Neuropeptide Y1 antagonist | |||
| 0.195 | 0.073 | 0.195 | Focal adhesion kinase 2 inhibitor | |||
| 0.13 | 0.009 | 0.13 | 5 Hydroxytryptamine 6 antagonist | |||
| 0.145 | 0.025 | 0.145 | Nitric-oxide synthase inhibitor | |||
| 0.176 | 0.058 | 0.176 | Arachidonic acid antagonist | 0.152 0.086 DBMET00900 | ||
| 0.162 | 0.044 | 0.162 | Adenylate cyclase stimulant | |||
| 0.144 | 0.028 | 0.144 | Acetylcholine agonist | |||
| 0.142 | 0.027 | 0.142 | Dopamine antagonist | |||
| 0.134 | 0.023 | 0.134 | 5 Hydroxytryptamine 1A antagonist | |||
| 0.134 | 0.027 | 0.134 | 5 Hydroxytryptamine 1 antagonist | |||
| 0.127 | 0.02 | 0.127 | 5 Hydroxytryptamine 7 antagonist | |||
| 0.215 | 0.108 | 0.215 | Spasmolytic | |||
| 0.12 | 0.014 | 0.12 | Acetylcholine muscarinic agonist | |||
| 0.114 | 0.009 | 0.114 | Nicotinic receptor alpha3 subunit antagonist | |||
| 0.307 | 0.204 | 0.307 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | |||
| 0.17 | 0.067 | 0.17 | Catenin beta inhibitor | |||
| 0.156 | 0.054 | 0.156 | Nav1.2 sodium channel blocker | |||
| 0.142 | 0.041 | 0.142 | Sphingosine 1-phosphate receptor 4 antagonist | |||
| 0.155 | 0.054 | 0.155 | Sphingosine 1-phosphate receptor 5 antagonist | |||
| 0.107 | 0.006 | 0.107 | Somatostatin 4 agonist | |||
| 0.11 | 0.01 | 0.11 | Glycine transporter inhibitor | |||
| 0.197 | 0.096 | 0.197 | Cyclic AMP phosphodiesterase inhibitor | |||
| 0.111 | 0.011 | 0.111 | Acetylcholine M1 receptor agonist | |||
| 0.127 | 0.028 | 0.127 | Acetylcholine nicotinic antagonist | |||
| 0.12 | 0.022 | 0.12 | Alpha adrenoreceptor agonist | |||
| 0.102 | 0.004 | 0.102 | Dopamine D5 agonist | |||
| 0.1 | 0.003 | 0.1 | Phenylethanolamine N methyltransferase inhibitor | 0.047 0.017 DBMET00900 | ||
| 0.208 | 0.111 | 0.208 | DNA synthesis inhibitor | |||
| 0.147 | 0.051 | 0.147 | Ca2+-transporting ATPase inhibitor | 0.141 0.069 DBMET00927 | ||
| 0.106 | 0.01 | 0.106 | NMDA receptor subunit 3B antagonist | |||
| 0.135 | 0.04 | 0.135 | Alpha 2c adrenoreceptor antagonist | |||
| 0.122 | 0.027 | 0.122 | Dopamine D2 antagonist | |||
| 0.101 | 0.008 | 0.101 | Myc inhibitor | |||
| 0.107 | 0.013 | 0.107 | Dopamine D4 agonist | |||
| 0.106 | 0.013 | 0.106 | Androgen agonist | |||
| 0.169 | 0.076 | 0.169 | 3C-like protease (Human coronavirus) inhibitor | |||
| 0.122 | 0.029 | 0.122 | Glutamate (mGluR7) agonist | |||
| 0.098 | 0.005 | 0.098 | Kainate receptor 2 antagonist | |||
| 0.113 | 0.022 | 0.113 | Dopamine agonist | |||
| 0.101 | 0.011 | 0.101 | Dopamine transporter inhibitor | |||
| 0.123 | 0.033 | 0.123 | Acetylcholine M3 receptor agonist | |||
| 0.103 | 0.014 | 0.103 | GABA B receptor agonist | |||
| 0.096 | 0.008 | 0.096 | 5 Hydroxytryptamine 7 agonist | |||
| 0.13 | 0.042 | 0.13 | Antiadrenergic | |||
| 0.094 | 0.006 | 0.094 | Glycine transporter 1 inhibitor | 0.053 0.014 DBMET00900 | ||
| 0.108 | 0.021 | 0.108 | Neuronal nicotinic receptor antagonist | |||
| 0.122 | 0.036 | 0.122 | Alpha 1 adrenoreceptor antagonist | |||
| 0.132 | 0.046 | 0.132 | TRPA1 agonist | 0.115 0.064 DBMET00927 | ||
| 0.126 | 0.042 | 0.126 | Adrenaline antagonist | |||
| 0.213 | 0.129 | 0.213 | Gastrin inhibitor | |||
| 0.143 | 0.06 | 0.143 | Sodium channel (voltage-gated) blocker | |||
| 0.112 | 0.03 | 0.112 | Acetylcholine nicotinic agonist | |||
| 0.111 | 0.03 | 0.111 | Bromodomain-containing protein 2 inhibitor | |||
| 0.156 | 0.075 | 0.194 | Anticoagulant | 0.194 0.055 DBMET00927 | DBMET00927 | |
| 0.181 | 0.102 | 0.181 | 5 Hydroxytryptamine 3E antagonist | |||
| 0.096 | 0.017 | 0.096 | 5 Hydroxytryptamine 3 agonist | |||
| 0.111 | 0.032 | 0.111 | Alpha 1a adrenoreceptor antagonist | |||
| 0.088 | 0.01 | 0.088 | Glutamate (mGluR group I) agonist | |||
| 0.083 | 0.008 | 0.083 | Histamine H4 receptor antagonist | |||
| 0.079 | 0.005 | 0.079 | Endothelial nitric-oxide synthase inhibitor | |||
| 0.118 | 0.044 | 0.118 | Antihistaminic | |||
| 0.144 | 0.07 | 0.144 | MAP3K9 inhibitor | |||
| 0.085 | 0.013 | 0.085 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.076 | 0.004 | 0.076 | Alpha 1L adrenoreceptor agonist | 0.046 0.023 DBMET00900 | ||
| 0.109 | 0.04 | 0.109 | Androgen antagonist | |||
| 0.156 | 0.087 | 0.156 | Neurotensin receptor agonist | |||
| 0.124 | 0.057 | 0.124 | Interleukin 8 antagonist | |||
| 0.087 | 0.023 | 0.087 | Acetylcholine M3 receptor antagonist | |||
| 0.129 | 0.065 | 0.129 | Nav1.3 sodium channel blocker | |||
| 0.224 | 0.16 | 0.224 | Vasodilator, coronary | |||
| 0.072 | 0.008 | 0.072 | GABA B receptor antagonist | |||
| 0.174 | 0.112 | 0.174 | Potassium channel blocker | |||
| 0.129 | 0.068 | 0.129 | Cyclooxygenase 3 inhibitor | |||
| 0.069 | 0.008 | 0.069 | AMPA 4 receptor antagonist | |||
| 0.083 | 0.022 | 0.083 | Exportin-1 inhibitor | |||
| 0.143 | 0.082 | 0.143 | Cholinergic | |||
| 0.19 | 0.129 | 0.19 | Superoxide dismutase inhibitor | |||
| 0.083 | 0.023 | 0.083 | 5 Hydroxytryptamine 3 antagonist | |||
| 0.122 | 0.063 | 0.122 | Cholesterol synthesis inhibitor | 0.113 0.072 DBMET00900 0.103 0.084 DBMET00927 | ||
| 0.074 | 0.015 | 0.074 | Nicotinic receptor alpha4 subunit antagonist | |||
| 0.089 | 0.029 | 0.089 | 5 Hydroxytryptamine 1B antagonist | |||
| 0.077 | 0.018 | 0.077 | Kallikrein 7 inhibitor | |||
| 0.087 | 0.029 | 0.088 | Vanilloid 4 agonist | 0.088 0.028 DBMET00900 | DBMET00900 | |
| 0.073 | 0.016 | 0.073 | Lysine-specific demethylase 1A inhibitor | |||
| 0.13 | 0.074 | 0.13 | Sodium channel blocker | |||
| 0.069 | 0.013 | 0.069 | Kainate receptor antagonist | |||
| 0.133 | 0.077 | 0.133 | Aurora-C kinase inhibitor | |||
| 0.181 | 0.126 | 0.181 | Nitric-oxide synthase stimulant | |||
| 0.097 | 0.043 | 0.097 | ALK inhibitor | |||
| 0.105 | 0.051 | 0.105 | Electrolyte absorption antagonist | |||
| 0.096 | 0.045 | 0.096 | ATPase (Vacuolar H+) inhibitor | 0.09 0.055 DBMET00927 | ||
| 0.138 | 0.089 | 0.138 | MAP kinase 3 inhibitor | |||
| 0.067 | 0.018 | 0.067 | Pregnane X receptor antagonist | |||
| 0.052 | 0.004 | 0.052 | Imidazoline I1 receptor antagonist | |||
| 0.075 | 0.027 | 0.075 | MDM2 inhibitor | |||
| 0.072 | 0.025 | 0.072 | GABA receptor antagonist | |||
| 0.086 | 0.039 | 0.086 | 5 Hydroxytryptamine 1F antagonist | |||
| 0.077 | 0.031 | 0.077 | Acetylcholine M2 receptor antagonist | |||
| 0.096 | 0.05 | 0.096 | Histamine N-methyltransferase inhibitor | |||
| 0.051 | 0.004 | 0.051 | Nicotinic alpha4beta2 receptor agonist | |||
| 0.067 | 0.021 | 0.067 | Histamine agonist | |||
| 0.068 | 0.023 | 0.068 | 5 Hydroxytryptamine 1A agonist | |||
| 0.05 | 0.005 | 0.05 | Nicotinic alpha3beta4 receptor agonist | |||
| 0.058 | 0.013 | 0.058 | Guanylate cyclase inhibitor | 0.04 0.033 DBMET00900 0.042 0.03 DBMET00927 | ||
| 0.068 | 0.024 | 0.068 | Glucosylceramidase inhibitor | |||
| 0.079 | 0.036 | 0.079 | Phospholipase D inhibitor | |||
| 0.099 | 0.056 | 0.099 | Prolactin inhibitor | |||
| 0.187 | 0.144 | 0.187 | Neuropeptide Y2 antagonist | |||
| 0.087 | 0.044 | 0.087 | CC chemokine 5 receptor agonist | |||
| 0.07 | 0.028 | 0.07 | Nicotinic neuronal receptor agonist | |||
| 0.098 | 0.056 | 0.098 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | |||
| 0.089 | 0.048 | 0.089 | Neuropeptide Y antagonist | |||
| 0.074 | 0.033 | 0.074 | Glutamate (mGluR6) antagonist | |||
| 0.055 | 0.015 | 0.055 | Factor XIa inhibitor | |||
| 0.058 | 0.019 | 0.058 | Potassium channel small-conductance Ca-activated blocker | |||
| 0.093 | 0.055 | 0.093 | Glutamate release inhibitor | |||
| 0.061 | 0.024 | 0.061 | AMPA receptor antagonist | |||
| 0.047 | 0.01 | 0.047 | AMPA 3 receptor antagonist | |||
| 0.055 | 0.019 | 0.055 | Purinergic P2X4 antagonist | |||
| 0.059 | 0.024 | 0.059 | 5 Hydroxytryptamine 4 antagonist | |||
| 0.051 | 0.017 | 0.051 | Histamine H1 receptor agonist | |||
| 0.063 | 0.029 | 0.063 | NMDA 2B receptor antagonist | |||
| 0.082 | 0.048 | 0.082 | Focal adhesion kinase 1 inhibitor | |||
| 0.061 | 0.027 | 0.061 | Sigma receptor antagonist | |||
| 0.067 | 0.034 | 0.067 | Calcium channel P-type blocker | |||
| 0.098 | 0.065 | 0.098 | Anabolic | |||
| 0.041 | 0.007 | 0.041 | 5 Hydroxytryptamine 6 agonist | |||
| 0.044 | 0.01 | 0.044 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | 0.025 0.021 DBMET00927 | ||
| 0.121 | 0.087 | 0.121 | Calcium channel blocker | 0.12 0.088 DBMET00900 | ||
| 0.048 | 0.015 | 0.048 | p53 inhibitor | |||
| 0.136 | 0.104 | 0.136 | CF transmembrane conductance regulator agonist | |||
| 0.087 | 0.057 | 0.087 | Histamine antagonist | |||
| 0.035 | 0.004 | 0.035 | NMDA receptor phencyclidine site antagonist | |||
| 0.053 | 0.023 | 0.053 | Adenylate cyclase 1 inhibitor | |||
| 0.095 | 0.066 | 0.095 | Sphingomyelinase inhibitor | |||
| 0.033 | 0.004 | 0.033 | Nicotinic alpha4 receptor agonist | |||
| 0.06 | 0.031 | 0.06 | GABA A receptor antagonist | |||
| 0.147 | 0.118 | 0.147 | Succinate dehydrogenase inhibitor | |||
| 0.067 | 0.039 | 0.067 | Dopamine D3 antagonist | |||
| 0.037 | 0.01 | 0.037 | LFA antagonist | 0.029 0.018 DBMET00900 | ||
| 0.052 | 0.025 | 0.052 | CC chemokine 4 receptor antagonist | |||
| 0.07 | 0.043 | 0.07 | Nav1.7 sodium channel blocker | |||
| 0.052 | 0.026 | 0.075 | Carnitine palmitoyltransferase 1B inhibitor | 0.075 0.009 DBMET00900 | DBMET00900 | |
| 0.064 | 0.039 | 0.064 | Phosphodiesterase 1C inhibitor | |||
| 0.107 | 0.081 | 0.107 | Sphingosine 1-phosphate receptor 2 agonist | |||
| 0.118 | 0.093 | 0.118 | Ribosomal protein S6 kinase inhibitor | |||
| 0.089 | 0.066 | 0.089 | Protein kinase C zeta inhibitor | |||
| 0.084 | 0.061 | 0.084 | Calcium antagonist | |||
| 0.072 | 0.049 | 0.072 | Benzodiazepine agonist | |||
| 0.077 | 0.054 | 0.077 | Estrogen receptor alpha antagonist | |||
| 0.094 | 0.071 | 0.094 | Check point kinase 2 inhibitor | |||
| 0.072 | 0.049 | 0.072 | Calcium channel L-type blocker | |||
| 0.063 | 0.041 | 0.063 | I kappa B kinase 2 inhibitor | |||
| 0.044 | 0.022 | 0.044 | Acid-sensing ion channel blocker | |||
| 0.049 | 0.027 | 0.049 | Glutamate (mGluR5) agonist | |||
| 0.031 | 0.01 | 0.031 | Kainate receptor 1 antagonist | |||
| 0.035 | 0.015 | 0.035 | Complement C5a chemotactic receptor antagonist | |||
| 0.043 | 0.023 | 0.043 | GABA uptake inhibitor | |||
| 0.08 | 0.06 | 0.08 | I kappa B kinase inhibitor | |||
| 0.076 | 0.057 | 0.076 | Glutamate receptor agonist | |||
| 0.046 | 0.028 | 0.046 | Dopamine D5 antagonist | |||
| 0.043 | 0.025 | 0.043 | Kainate receptor agonist | |||
| 0.045 | 0.029 | 0.045 | Dipeptidyl peptidase IV inhibitor | |||
| 0.052 | 0.036 | 0.052 | NMDA 2A receptor antagonist | |||
| 0.023 | 0.008 | 0.023 | Histone-lysine N-methyltransferase EZH2 inhibitor | |||
| 0.033 | 0.018 | 0.033 | AMPA 1 receptor antagonist | |||
| 0.052 | 0.038 | 0.052 | Dipeptidyl peptidase inhibitor | |||
| 0.038 | 0.024 | 0.038 | Integrin alpha2 antagonist | |||
| 0.043 | 0.029 | 0.043 | Nerve growth factor antagonist | |||
| 0.112 | 0.098 | 0.112 | Toll-Like receptor antagonist | |||
| 0.089 | 0.076 | 0.089 | Bile acid receptor antagonist | |||
| 0.029 | 0.016 | 0.029 | Myristoyl transferase inhibitor | |||
| 0.066 | 0.056 | 0.066 | Alpha 1b adrenoreceptor antagonist | |||
| 0.074 | 0.064 | 0.074 | Histamine H1 receptor antagonist | |||
| 0.056 | 0.046 | 0.056 | Heat shock protein 90 beta antagonist | |||
| 0.044 | 0.034 | 0.044 | Phosphorylase inhibitor | |||
| 0.034 | 0.024 | 0.034 | Factor XI inhibitor | |||
| 0.032 | 0.022 | 0.032 | ATP citrate lysase inhibitor | |||
| 0.025 | 0.016 | 0.025 | Glutamate (mGluR1) agonist | |||
| 0.05 | 0.041 | 0.05 | Toll-Like receptor 8 antagonist | |||
| 0.051 | 0.043 | 0.051 | CC chemokine 2 receptor antagonist | |||
| 0.058 | 0.05 | 0.058 | NMDA receptor agonist | |||
| 0.033 | 0.026 | 0.033 | Progesterone antagonist | |||
| 0.05 | 0.043 | 0.05 | Nicotinic receptor alpha7 subunit antagonist | |||
| 0.019 | 0.013 | 0.019 | Alpha 2c adrenoreceptor agonist | |||
| 0.081 | 0.075 | 0.081 | Pim-3 kinase inhibitor | |||
| 0.018 | 0.012 | 0.018 | Cyclin T1 inhibitor | |||
| 0.033 | 0.028 | 0.033 | Arginase inhibitor | |||
| 0.02 | 0.015 | 0.02 | Thymidine kinase (Herpes simplex virus 2) inhibitor | |||
| 0.068 | 0.063 | 0.068 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | |||
| 0.067 | 0.062 | 0.067 | Na+ K+ transporting ATPase inhibitor | |||
| 0.04 | 0.035 | 0.04 | GHS receptor agonist | |||
| 0.018 | 0.013 | 0.018 | Histamine H4 receptor agonist | |||
| 0.022 | 0.017 | 0.022 | Motilin receptor agonist | |||
| 0.029 | 0.025 | 0.029 | Epoxide hydrolase 1 inhibitor | |||
| 0.037 | 0.032 | 0.037 | Integrin alpha1beta1 antagonist | |||
| 0.091 | 0.087 | 0.091 | Cystathionine beta-synthase inhibitor | |||
| 0.061 | 0.057 | 0.061 | Check point kinase 1 inhibitor | |||
| 0.056 | 0.053 | 0.056 | Enoyl-[acyl-carrier-protein] reductase inhibitor | |||
| 0.073 | 0.07 | 0.073 | Opioid kappa receptor antagonist | |||
| 0.023 | 0.019 | 0.023 | Kainate receptor 4 antagonist | |||
| 0.051 | 0.049 | 0.051 | Alpha 1 adrenoreceptor agonist | |||
| 0.078 | 0.076 | 0.078 | 3C-Like protease (SARS coronavirus) inhibitor | |||
| 0.056 | 0.055 | 0.056 | Bcl-xL inhibitor | |||
| 0.054 | 0.053 | 0.054 | Ca(v)3.2 blocker | |||
| 0.083 | 0.082 | 0.083 | MAP kinase kinase 1 inhibitor | |||
| 0.043 | 0.042 | 0.043 | 5 Hydroxytryptamine 1 agonist | |||
| 0.009 | 0.008 | 0.009 | Progesterone receptor A antagonist | |||
| 0.03 | 0.031 | 0.036 | ADAM10 endopeptidase inhibitor | 0.036 0.019 DBMET00927 | DBMET00927 | |
| 0.112 | 0.113 | 0.179 | Cell wall synthesis inhibitor | 0.179 0.041 DBMET00900 | DBMET00900 | |
| 0.031 | 0.039 | 0.082 | Glutamate (mGluR8) antagonist | 0.082 0.003 DBMET00927 | DBMET00927 | |
| 0.141 | 0.155 | 0.205 | Platelet antagonist | 0.205 0.098 DBMET00927 | DBMET00927 | |
| 0.186 | 0.215 | 0.262 | Interleukin 2 agonist | 0.262 0.106 DBMET00927 | DBMET00927 | |
| 0.031 | 0.075 | 0.109 | Protein 50S ribosomal subunit inhibitor | 0.109 0.011 DBMET00927 | DBMET00927 | |
| 0.074 | 0.137 | 0.104 | Toll-Like receptor 4 antagonist | 0.104 0.063 DBMET00927 | DBMET00927 | |
| 0.146 | 0.26 | 0.288 | Immunosuppressant | 0.288 0.123 DBMET00927 | DBMET00927 | |
| 0.049 | 0.166 | 0.076 | Cell adhesion molecule inhibitor | 0.076 0.059 DBMET00927 | DBMET00927 | |
| 0.069 | 0.199 | 0.157 | Cell adhesion inhibitor | 0.157 0.043 DBMET00927 | DBMET00927 | |
| 0.156 | 0.29 | 0.428 | Antibacterial | 0.371 0.091 DBMET00900 0.428 0.065 DBMET00927 | DBMET00927 | |
| 0.083 | 0.227 | 0.135 | Nitric oxide antagonist | 0.135 0.112 DBMET00927 | DBMET00927 | |
| 0.016 | 0.159 | 0.035 | Purinergic P2Y2 antagonist | 0.035 0.021 DBMET00900 | DBMET00900 | |
| 0.005 | 0.156 | 0.058 | Squalene synthetase inhibitor | 0.058 0.012 DBMET00927 | DBMET00927 | |
| 0.004 | 0.159 | 0.045 | Estrone sulfatase inhibitor | 0.045 0.008 DBMET00900 | DBMET00900 | |
| 0.005 | 0.178 | 0.244 | Urotensin II antagonist | 0.244 0.004 DBMET00900 | DBMET00900 | |
| 0.142 | 0.376 | 0.351 | Apoptosis agonist | 0.351 0.138 DBMET00927 | DBMET00927 | |
| 0.03 | 0.282 | 0.059 | Adenine nucleotide translocase inhibitor | 0.059 0.03 DBMET00927 | DBMET00927 | |
| 0.077 | 0.371 | 0.186 | Hypoglycemic | 0.186 0.127 DBMET00927 | DBMET00927 | |
| 0.12 | 0.425 | 0.483 | Cyclophilin D inhibitor | 0.483 0.055 DBMET00927 | DBMET00927 | |
| 0.103 | 0.408 | 0.282 | Peptidyltransferase inhibitor | 0.282 0.032 DBMET00927 | DBMET00927 | |
| 0.056 | 0.385 | 0.146 | Hepatoprotectant | 0.146 0.114 DBMET00927 | DBMET00927 | |
| 0.041 | 0.393 | 0.362 | Hypolipemic | 0.362 0.032 DBMET00900 0.282 0.055 DBMET00927 | DBMET00900 | |
| 0.013 | 0.422 | 0.037 | Antibiotic Aminoglycoside-like | 0.037 0.025 DBMET00927 | DBMET00927 | |
| 0.027 | 0.476 | 0.24 | Angiogenesis stimulant | 0.24 0.075 DBMET00927 | DBMET00927 | |
| 0.027 | 0.503 | 0.18 | DNA polymerase I inhibitor | 0.18 0.035 DBMET00927 | DBMET00927 | |
| 0.023 | 0.524 | 0.371 | Beta lactamase inhibitor | 0.371 0.109 DBMET00900 | DBMET00900 | |
| 0.029 | 0.544 | 0.206 | Antioxidant | 0.206 0.11 DBMET00927 | DBMET00927 | |
| 0.022 | 0.546 | 0.172 | Free radical scavenger | 0.172 0.122 DBMET00927 | DBMET00927 | |
| 0.005 | 0.555 | 0.055 | Selectin antagonist | 0.055 0.054 DBMET00927 | DBMET00927 | |
| 0.01 | 0.756 | 0.163 | Amyloid beta precursor protein antagonist | 0.163 0.087 DBMET00927 | DBMET00927 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |